69567-10-8
69567-10-8 結(jié)構(gòu)式
基本信息
N-甲基-1-脫氧尻霉素
1,5-二脫氧-1,5-亞氨基-1-甲基-D-山梨醇
N-MDJN
MOR-14
Aids000354
Aids-000354
N-Methylmoranolin
N-METHYLDEOXYNOJIRIMYCIN
DEOXYNOJIRIMYCIN, N-METHYL-
N-METHYL-1-DEOXYNOJIRIMYCIN
N-METHYL-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL
物理化學性質(zhì)
安全數(shù)據(jù)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/06/05 | HY-U00090 | 丙二腈 N-Methylmoranoline | 69567-10-8 | 1 mg | 1818元 |
| 2026/06/05 | HY-U00090 | 丙二腈 N-Methylmoranoline | 69567-10-8 | 5mg | 4000元 |
| 2024/08/19 | HY-U00090 | 丙二腈 N-Methylmoranoline | 69567-10-8 | 10mg | 6500元 |
常見問題列表
N-Methylmoranoline dose-dependently decreases the α-1,6-glucosidase activity in rabbit heart extract. The myocardial uptake of a considerable amount of N-Methylmoranoline is sufficient to fully inhibit alpha-1,6-glucosidase. Preischemic treatment with 25, 50, and 100 mg/kg of N-Methylmoranoline dose-dependently reduces the infarct size without altering the blood pressure or heart rate. MOR-14 significantly increases levels of PKC-ε in the particulate fraction at 20 and 30?min of ischaemia and in the cytosolic fraction at 30?min of ischaemia.
N-Methylmoranoline decreases the alpha-1,6-glucosidase activity to approximately 20%, reduces the glycogen breakdown, and attenuates the lactate accumulation at both 10 and 30 minutes of ischemia. MOR-14 is protective against postischemic left ventricular dysfunction through the inhibition of glycogenolysis in the isolated rat heart.